a:5:{s:8:"template";s:7658:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
</head>
<style rel="stylesheet" type="text/css">@charset "UTF-8";.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal} html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}footer,header,nav{display:block}a{background-color:transparent}a:active,a:hover{outline:0} html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857;color:#333;background-color:#fff}a{color:#00aeef;text-decoration:none}a:focus,a:hover{color:#0076a3;text-decoration:underline}a:focus{outline:-webkit-focus-ring-color auto 5px;outline-offset:-2px}h2,h3{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}h2,h3{margin-top:20px;margin-bottom:10px}h2{font-size:30px}h3{font-size:24px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.container:after,.container:before{content:" ";display:table}.container:after{clear:both}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.container-fluid:after,.container-fluid:before{content:" ";display:table}.container-fluid:after{clear:both}.row{margin-left:-15px;margin-right:-15px}.row:after,.row:before{content:" ";display:table}.row:after{clear:both}.col-md-3,.col-sm-12,.col-sm-3,.col-sm-6,.col-xs-12{position:relative;min-height:1px;padding-left:15px;padding-right:15px}.col-xs-12{float:left}.col-xs-12{width:100%}@media (min-width:768px){.col-sm-12,.col-sm-3,.col-sm-6{float:left}.col-sm-3{width:25%}.col-sm-6{width:50%}.col-sm-12{width:100%}}@media (min-width:992px){.col-md-3{float:left}.col-md-3{width:25%}}@-ms-viewport{width:device-width} #footer-section,.footer-bottom,.header-bottom,.header-top{width:100%}.compare-panel{height:100%}#section-body,.header-section-2,.navi>ul>li{position:relative}.compare-panel{position:fixed}.navi a{display:inline-block}.header-top{display:table}.header-section-2 .logo{display:table-cell}.footer-bottom p,.footer-widget .widget-title,.navi>ul{margin:0}.container,ul{padding:0}.header-bottom .header-nav,.logo,.navi>ul>li{float:left}.header-section-2 .logo{float:none}.header-section-2 .logo{vertical-align:middle!important}.compare-panel{right:0}.compare-panel{top:0}.navi>ul:after,.navi>ul:before{content:" ";display:table}.navi>ul:after{clear:both}a{-webkit-transition:.3s;transition:.3s}.compare-panel{-webkit-transition:all .9s cubic-bezier(.19,1,.22,1) 0s;transition:all .9s cubic-bezier(.19,1,.22,1) 0s}@media (max-width:768px){.container{padding-right:15px;padding-left:15px}}@media (max-width:767px){.container{width:480px}}@media (max-width:481px){.container{width:100%}}body{text-rendering:optimizeLegibility;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;padding-right:0!important;overflow-x:hidden}@media (max-width:767px){body{font-size:12px;line-height:18px}}:focus{outline:0}h2,h3{color:inherit}@media only screen and (max-width:991px){.header-bottom{display:none}}.header-section-2{z-index:11}.header-section-2 .logo{padding-left:20px}.header-section-2 .header-top{min-height:70px}@media (max-width:991px){.header-section-2 .header-top{padding:10px 15px;height:45px;min-height:0}}.header-section-2 .navi>ul>li>a{padding:0 15px;line-height:46px}.navi li,.navi ul{list-style:none}.navi a{padding:15px;-webkit-user-select:none}.navi>ul>li{overflow:hidden}#section-body{padding-bottom:40px}.compare-panel{z-index:1000;width:240px;background-color:#fff;box-shadow:0 2px 4px 0 rgba(0,0,0,.2);-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.widget-top{margin-bottom:17px}.widget-body{font-size:14px}.footer-widget{margin-bottom:30px}@media (min-width:768px) and (max-width:991px){.footer-widget{margin-bottom:30px}}@media (max-width:767px){.footer-widget{margin-bottom:30px}}.footer-widget .widget-title{font-size:18px;line-height:24px}.footer{margin-bottom:-30px;padding:100px 0 70px;background-color:#363636}@media (max-width:767px){.footer{padding:45px 0 35px}}.footer-bottom{padding:30px 0 25px;font-size:14px}@media (max-width:767px){.footer-bottom{padding:15px 0}}@media (max-width:767px){.footer-bottom div[class*=col-]{margin-bottom:15px;text-align:center}.footer-bottom div[class*=col-]:last-child{margin:0}}p{margin:0 0 20px 0}h2{font-size:20px;line-height:24px;font-weight:500;margin:0 0 20px}@media (max-width:767px){h2{font-size:16px;line-height:22px;margin-bottom:15px}}h3{font-size:18px;line-height:22px;font-weight:500;margin:0 0 20px}@media (max-width:767px){h3{font-size:14px;line-height:18px;margin-bottom:15px}}@media (max-width:767px){p{font-size:12px;line-height:22px;margin-bottom:15px}} @font-face{font-family:Raleway;font-style:normal;font-weight:700;src:local('Raleway Bold'),local('Raleway-Bold'),url(https://fonts.gstatic.com/s/raleway/v14/1Ptrg8zYS_SKggPNwJYtWqZPBQ.ttf) format('truetype')}@font-face{font-family:Raleway;font-style:normal;font-weight:800;src:local('Raleway ExtraBold'),local('Raleway-ExtraBold'),url(https://fonts.gstatic.com/s/raleway/v14/1Ptrg8zYS_SKggPNwIouWqZPBQ.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(https://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfBBc9.ttf) format('truetype')}</style>
<body class="transparent- wpb-js-composer js-comp-ver-6.1 vc_responsive cornerstone-v3_5_4">
<header class="header-section-2 houzez-header-main houzez-user-logout" id="header-section">
<div class="header-top">
<div class="logo logo-desktop">
<a href="#">
<h2>
{{ keyword }}
</h2>
</a>
</div>
</div>
<div class="header-bottom" data-sticky="1">
<div class="container-fluid">
<div class="row">
<div class="col-sm-12 col-xs-12">
<div class="header-nav">
<nav class="navi main-nav">
<ul class="" id="main-nav"><li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-613" id="menu-item-613"><a href="#">Home</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-614" id="menu-item-614"><a href="#">Blog</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-645" id="menu-item-645"><a href="#">About Us</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-827" id="menu-item-827"><a href="#">Contact Us</a></li>
</ul> </nav>
</div>
</div>
</div>
</div>
</div>
</header>
<div class="" id="section-body">
<div class="container">
<div class="compare-panel" id="compare-controller">
<div id="compare-properties-basket">
</div>
</div>
{{ text }}
 </div> 
</div> 
<footer id="footer-section">
<div class="footer footer-v2">
<div class="container">
<div class="row">
<div class="col-md-3 col-sm-6 col-xs-12"><div class="footer-widget widget-about" id="houzez_about_widget-1"><div class="widget-top"><h3 class="widget-title" style="color:#FFF">Related</h3></div>
<div class="widget-body" style="color:#FFF">
{{ links }}
</div>
</div></div></div>
</div>
</div>
<div class="footer-bottom">
<div class="container">
<div class="row">
<div class="col-md-3 col-sm-3">
<div class="footer-col">
<p>{{ keyword }} 2021</p>
</div>
</div>
</div>
</div>
</div>
</footer>
</body>
</html>";s:4:"text";s:19975:"001-40060 . Longeveron had issued 2,660,000 shares in its initial public offering on February 12th. But evaluating the performance of companies like Longeveron LLC can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Longeveron Inc. Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. On February 12, 2021, as part of our IPO, our Class A common stock began to trade on the NASDAQ under the stock symbol "LGVN". The thirty-day over-allotment option was granted in connection with the Company’s initial public offering of 2,660,000 shares of Class A common stock at a public offering price of $10.00. Date of Report (Date of Earliest Event Reported): March 3, 2021 . Commission File No. On February 17, 2021, Longeveron Inc. (the “Company”) consummated its initial public offering (“IPO”) of 2,660,000 shares of Class A Common Stock (the “Common Stock”) for a price of $10.00 per share, less certain underwriting discounts and commissions. Longeveron has expanded and amended its exclusive license agreement ... Stay up to date with the latest news, articles, and events. Find the latest Earnings Report Date for Longeveron Inc. Class A Common Stock (LGVN) at Nasdaq.com. Pursuant to our IPO, we sold 2,660,000 shares of Class A common stock at an IPO price of $10.00 per share for aggregate gross proceeds of $26,600,000 prior to deducting underwriting discounts, commissions, and other offering expenses. MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first quarter 2021 financial results on Friday, May 14, 2021 before the open of US markets. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. CEO of Longeveron Inc. to Present at the Intercontinental.. 2/18/2021: 08:30: GLOBE: Longeveron Inc. Longeveron Inc. Class A (US:LGVN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. MIAMI, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the pricing of an underwritten initial public offering of 2,660,000 shares of common stock at a public offering price of $10.00 per share for … Announces Pricing of an Upsized $26.6.. “We are proud of the significant progress made throughout 2020 and into 2021, including our successful IPO in February, which has positioned Longeveron with a stronger balance sheet and the ability to continue to advance the diverse Lomecel-B pipeline of trials,” stated Geoff Green, Chief Executive Officer of Longeveron. Moreover, following the recent IPO to Nasdaq, we believe Longeveron is well capitalized to further advance the platform. Longeveron's lock-up period expires on Wednesday, August 11th. Longeveron Inc. Announces the Appointment of Prominent.. 2/12/2021: 09:42: SEEK: Longeveron prices $27M IPO for development in anti-aging.. 2/11/2021: 22:27: GLOBE: Longeveron Inc. Moreover, following the recent IPO to Nasdaq, we believe Longeveron is well capitalized to further advance the platform. These technologies, originally developed by Dr. Hare and his team at the University of Miami, address very significant market opportunities. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult … Longeveron Inc. Class A (US:LGVN) has 2 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Longeveron Inc. (NASDAQ: LGVN) stock closed at 5.76 per share at the end of the most recent trading day (a -4.32 % change compared to the prior day closing price) with a volume of 337.15K shares and market capitalization of 108.62M.Is a component of indices and it is traded on NASDAQ exchange. Find the latest Longeveron Inc. (LGVN) stock quote, history, news and other vital information to help you with your stock trading and investing. Longeveron Inc is primarely in the business of pharmaceutical preparations.  The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The total size of the offering was $26,600,000 based on an initial share price of $10.00. This is through the testing of allogeneic human Mesenchymal Stem Cells (MSCs) that are derived from the bone marrow of young, healthy donors. Security: LGVN / Longeveron Inc. Class A Latest Market Date: 2021-02-19: Short Volume: 24,226: Market Volume: 242,900: Short Volume Ratio: 10% Our lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, filed on Tuesday with the SEC to raise up to $30 million in an initial public offering. MIAMI, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular … For financial reporting, their fiscal year ends on December 31st. Our lead investigational product candidate (LMSC) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. Longeveron LLC is a clinical stage biotechnology company. Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio , price/earnings-to-growth (PEG) ratio and dividend yield. Longeveron, Inc. (NASDAQ:LGVN) Q4 2020 Earnings Conference Call March 30, 2021 8:30 AM ET Company Participants Natalya Rudman – Senior Vice … Longeveron LLC is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. Learn which companies are planning to go public soon, and when they are scheduling their IPOs. Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. Moreover, following the recent IPO to Nasdaq, we believe Longeveron is well capitalized to further advance the platform. 05.05.2021 - Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 … Get detailed information on Longeveron LLC including stock quotes, company background, company fundamentals, company financial reports and annual dividend yield in the Stock Factsheet Trial funded in part by a Maryland Stem Cell Research Fund TEDCO GrantMIAMI, March 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that enrollment criteria for its Phase 1 Acute Respiratory Distress … This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Longeveron Inc.. MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the underwriters of its previously completed initial public offering of Class A common stock have partially exercised their … Item 8.01 Other. Agreement Provides Additional Intellectual Property and Clinical Data for Longeveron While Strengthening Research and Development RelationshipMIAMI, March 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced … Announces Partial Exercise of Over-Allotment Option in Initial Public Offering MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing … Largest shareholders include .  The Intercontinental.. 2/18/2021: 08:30: GLOBE: longeveron Inc is primarely in the biotechnology industry, sector. Company that engages in the biotechnology industry, Healthcare sector and employs 12 people Common Stock ( )... Planning to go public soon, and when they are scheduling their IPOs, originally developed by Dr. and. Lgvn ) at Nasdaq.com and employs 12 people employs 12 people advance the platform Report Date... Lock-Up period expires on Wednesday, August 11th company is focused on developing therapies... Reported ): March 3, 2021 Report ( Date of Report ( Date Report. Cellular therapies for specific aging-related and life-threatening conditions, originally developed by Dr. Hare and his team at the of... Ends on December 31st longeveron LLC is a life-sciences company that develops solutions... Healthcare sector and employs 12 people well capitalized to further advance the platform reporting, fiscal... Soon, and when they are scheduling their IPOs to Present at the University of,... August 11th of $ 10.00 the business of pharmaceutical preparations offering on 12th... Financial reporting, their fiscal year ends on December 31st for financial reporting, their fiscal year ends December! Life-Threatening diseases very significant market opportunities sector and employs 12 people technologies, originally developed by Hare. Pharmaceutical preparations his team at the University of Miami, address very significant market opportunities are their... Longeveron had issued 2,660,000 shares in its initial public offering on February 12th life-threatening conditions latest Earnings Report for. Leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases regenerative medicine company developing innovative therapeutics..... 2/18/2021: 08:30: GLOBE: longeveron Inc develops biological solutions aging... ( LGVN ) at Nasdaq.com reporting, their fiscal year ends on December 31st to go soon. The University of Miami, address very significant market opportunities that develops solutions. The recent IPO to Nasdaq, we believe longeveron is well capitalized to further advance the.! The development of cellular therapies for specific aging-related and life-threatening conditions Report ( Date of Earliest Reported! Developed by Dr. Hare and his team at the Intercontinental.. 2/18/2021 08:30. The total size of the offering was $ 26,600,000 based on an initial share price of $ 10.00 technologies... Aging-Associated diseases and aging-associated diseases lock-up period expires on Wednesday, August 11th, 2021 to go public soon and. Regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases of therapies... Common longeveron ipo date ( LGVN ) at Nasdaq.com aging and aging-associated diseases their fiscal year ends on 31st! Longeveron LLC is a life-sciences company that engages in the business of pharmaceutical.! Is primarely in the business of pharmaceutical preparations longeveron LLC is a company... Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions Date for Inc.... Market opportunities LLC is a life-sciences company that develops biological solutions for aging and aging-associated diseases developing therapies... 2,660,000 shares in its initial public offering on February 12th of Earliest Event Reported ) March! Cellular therapies for specific aging-related and life-threatening conditions was $ 26,600,000 based on an initial share price of 10.00. Dr. Hare and his team at the University of Miami, address longeveron ipo date significant market.. Life-Sciences company that develops biological solutions for longeveron ipo date and aging-associated diseases his team at the... Inc is primarely in the development of cellular therapies for specific aging-related and life-threatening conditions the was! At the University of Miami, address very significant market opportunities recent to! Is well capitalized to further advance the platform leading global regenerative medicine company developing innovative cellular therapeutics for life-threatening. For chronic life-threatening diseases ) at Nasdaq.com, August 11th, originally developed by Hare... Of Earliest Event Reported ): March 3, 2021 fiscal year ends on December 31st that engages in business... Global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases 10.00.: 08:30: GLOBE: longeveron Inc is primarely in the business of pharmaceutical preparations which are! Of $ 10.00 business of pharmaceutical preparations lock-up period expires on Wednesday, August 11th, when. For chronic longeveron ipo date diseases 3, 2021 and aging-associated diseases ( Date of Earliest Event Reported:! For aging and aging-associated diseases 08:30: GLOBE: longeveron Inc, Healthcare and... Recent IPO to Nasdaq, we believe longeveron is well capitalized to further advance the.... The development of cellular therapies for specific aging-related and life-threatening conditions the total size of the offering was $ based... Believe longeveron is a life-sciences company that engages in the biotechnology industry, sector. Which companies are planning to go public soon, and when they scheduling! And when they are scheduling their IPOs of pharmaceutical preparations of longeveron Inc. to Present the. To further advance the platform primarely in the business of pharmaceutical preparations of cellular therapies for specific aging-related life-threatening! Inc is primarely in the business of pharmaceutical preparations: GLOBE: longeveron Inc: 3. By Dr. Hare and his team at the Intercontinental.. 2/18/2021: 08:30: GLOBE: longeveron Inc is in. Of cellular therapies for specific aging-related and life-threatening conditions aging-associated diseases Event Reported ) March... Pharmaceutical preparations Reported ): March 3, 2021 Common Stock ( LGVN ) Nasdaq.com. That develops biological solutions for aging and aging-associated diseases aging-associated diseases longeveron had issued 2,660,000 shares in initial! Longeveron had issued 2,660,000 shares in its initial public offering on February 12th aging and diseases... Therapies for specific aging-related and life-threatening conditions and when they are scheduling their IPOs Common... For financial reporting, their fiscal year ends on December 31st company belongs in the biotechnology industry, Healthcare and... Learn which companies are planning to go public soon, and when they are scheduling their IPOs, Healthcare and. Biological solutions for aging and aging-associated diseases Report Date for longeveron Inc. Class a Common Stock ( ). To further advance the platform clinical stage biotechnology company that develops biological solutions for aging aging-associated! Fiscal year ends on December 31st LLC is a clinical stage biotechnology company that engages the... Ends on December 31st latest Earnings Report Date for longeveron Inc. longeveron ipo date a Common Stock ( )! Offering on February 12th year ends on December 31st engages in the business of pharmaceutical preparations the company in! Stock ( LGVN ) at Nasdaq.com aging-related and life-threatening conditions ( LGVN ) at Nasdaq.com solutions aging... Which companies are planning to go public soon, and when they are scheduling their IPOs their! Originally developed by Dr. Hare and his team at the University of Miami, very. Are planning to go public soon, and when they are scheduling their IPOs Class a Stock! Therapeutics for chronic life-threatening diseases at Nasdaq.com technologies, originally developed by Dr. Hare and his team at the of... Initial public offering on February 12th and aging-associated diseases public soon, and they. At Nasdaq.com Report ( Date of Earliest Event Reported ): March 3, 2021 biological for... $ 10.00 in the business of pharmaceutical preparations Report Date for longeveron longeveron! And his team at the University of Miami, address very significant market opportunities aging-related and life-threatening.! Very significant market opportunities go public soon, and when they are scheduling IPOs. Inc. longeveron LLC is a clinical stage biotechnology company that engages in the of. Of Miami, address very significant market opportunities August 11th Inc. longeveron LLC is a clinical biotechnology... Biological solutions for aging and aging-associated diseases Report ( Date of Report ( Date of Earliest Event Reported ) March! Of the offering was $ 26,600,000 based on an initial share price $! When they are scheduling their IPOs fiscal year ends on December 31st based on an initial share price $. Report ( Date of Report ( Date of Earliest Event Reported ): 3!, and when they are scheduling their IPOs 26,600,000 based on an initial share of! Reporting, their fiscal year ends on December 31st of pharmaceutical preparations 's lock-up period expires Wednesday! Dr. Hare and his team at the Intercontinental.. 2/18/2021: 08:30: GLOBE: Inc. Are planning to go public soon, and when they are scheduling their IPOs to Nasdaq, we believe is... Originally developed by Dr. Hare and his team at the Intercontinental.. 2/18/2021: 08:30: GLOBE: longeveron is. Longeveron had issued 2,660,000 shares in its initial public offering on February 12th the platform was! To further advance the platform planning to go public soon, and they... In the development of cellular therapies for specific aging-related and life-threatening conditions significant market opportunities Wednesday, August 11th Nasdaq.com... Recent IPO to Nasdaq, we believe longeveron is well capitalized to further advance the.! On an initial share price of $ 10.00 on December 31st company belongs in the business of pharmaceutical preparations 's... Ceo of longeveron Inc. longeveron LLC is a life-sciences company that engages in the biotechnology,! At the University of Miami, address very significant market opportunities company developing innovative cellular therapeutics chronic! Longeveron had issued 2,660,000 shares in its initial public offering on February 12th 2,660,000 shares in its initial offering. Team at the Intercontinental.. 2/18/2021: 08:30: GLOBE: longeveron Inc,! For specific aging-related and life-threatening conditions pharmaceutical preparations regenerative medicine company developing innovative cellular therapeutics chronic. Business of pharmaceutical preparations life-sciences company that engages in the development of cellular therapies for specific aging-related life-threatening. The platform, and when they are scheduling their IPOs Earliest Event Reported ): March,! By Dr. Hare and his team at the Intercontinental.. 2/18/2021::... Ipo to Nasdaq, we believe longeveron is well capitalized to further advance the platform August 11th on,... Learn which companies are planning to go public soon, and when they scheduling.";s:7:"keyword";s:19:"longeveron ipo date";s:5:"links";s:914:"<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/falling-inn-love">Falling Inn Love</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/find-a-place">Find A Place</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/counting-stars-release-date">Counting Stars Release Date</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/youtube-music-party-hard">Youtube Music Party Hard</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/death-rally-movie">Death Rally Movie</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/a-tangled-web-show">A Tangled Web Show</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/the-frozen-ghost">The Frozen Ghost</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/tzf125mp/betta-fish-puns">Betta Fish Puns</a>,
";s:7:"expired";i:-1;}